O	0	10	Activation	Activation	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	22	vascular	vascular	JJ	B-NP
O	23	34	endothelial	endothelial	JJ	I-NP
O	35	41	growth	growth	NN	I-NP
O	42	48	factor	factor	NN	I-NP
O	49	56	through	through	IN	B-PP
O	57	65	reactive	reactive	JJ	B-NP
O	66	72	oxygen	oxygen	NN	I-NP
O	73	80	species	specie	NNS	I-NP
O	81	89	mediates	mediate	VBZ	B-VP
O	90	92	20	20	CD	B-NP
O	92	93	-	-	HYPH	I-NP
O	93	116	hydroxyeicosatetraenoic	hydroxyeicosatetraenoic	JJ	I-NP
O	117	121	acid	acid	NN	I-NP
O	121	122	-	-	HYPH	O
O	122	129	induced	induce	VBN	B-NP
B-Cell	130	141	endothelial	endothelial	JJ	I-NP
I-Cell	142	146	cell	cell	NN	I-NP
O	147	160	proliferation	proliferation	NN	I-NP
O	160	161	.	.	.	O

O	162	164	20	20	CD	B-NP
O	164	165	-	-	HYPH	I-NP
O	165	188	Hydroxyeicosatetraenoic	Hydroxyeicosatetraenoic	JJ	I-NP
O	189	193	acid	acid	NN	I-NP
O	194	195	(	(	(	O
O	195	197	20	20	CD	B-NP
O	197	198	-	-	HYPH	I-NP
O	198	202	HETE	HETE	NN	I-NP
O	202	203	)	)	)	O
O	204	206	is	be	VBZ	B-VP
O	207	213	formed	form	VBN	I-VP
O	214	216	by	by	IN	B-PP
O	217	220	the	the	DT	B-NP
O	221	226	omega	omega	SYM	I-NP
O	226	227	-	-	HYPH	I-NP
O	227	240	hydroxylation	hydroxylation	NN	I-NP
O	241	243	of	of	IN	B-PP
O	244	255	arachidonic	arachidonic	JJ	B-NP
O	256	260	acid	acid	NN	I-NP
O	261	263	by	by	IN	B-PP
O	264	274	cytochrome	cytochrome	NN	B-NP
O	275	279	P450	P450	NN	I-NP
O	280	282	4A	4A	NN	I-NP
O	283	286	and	and	CC	I-NP
O	287	289	4F	4F	NN	I-NP
O	290	297	enzymes	enzyme	NNS	I-NP
O	297	298	,	,	,	O
O	299	302	and	and	CC	O
O	303	305	it	it	PRP	B-NP
O	306	313	induces	induce	VBZ	B-VP
O	314	324	angiogenic	angiogenic	JJ	B-NP
O	325	334	responses	response	NNS	I-NP
O	335	337	in	in	FW	B-ADVP
O	338	342	vivo	vivo	FW	I-ADVP
O	342	343	.	.	.	O

O	344	346	To	To	TO	B-VP
O	347	351	test	test	VB	I-VP
O	352	355	the	the	DT	B-NP
O	356	366	hypothesis	hypothesis	NN	I-NP
O	367	371	that	that	IN	B-SBAR
O	372	374	20	20	CD	B-NP
O	374	375	-	-	HYPH	I-NP
O	375	379	HETE	HETE	NN	I-NP
O	380	389	increases	increase	VBZ	B-VP
B-Cell	390	401	endothelial	endothelial	JJ	B-NP
I-Cell	402	406	cell	cell	NN	I-NP
O	407	408	(	(	(	O
B-Cell	408	410	EC	EC	NN	B-NP
O	410	411	)	)	)	O
O	412	425	proliferation	proliferation	NN	B-NP
O	426	429	via	via	IN	B-PP
O	430	438	vascular	vascular	JJ	B-NP
O	439	450	endothelial	endothelial	JJ	I-NP
O	451	457	growth	growth	NN	I-NP
O	458	464	factor	factor	NN	I-NP
O	465	466	(	(	(	O
O	466	470	VEGF	VEGF	NN	B-NP
O	470	471	)	)	)	O
O	471	472	,	,	,	O
O	473	475	we	we	PRP	B-NP
O	476	483	studied	study	VBD	B-VP
O	484	487	the	the	DT	B-NP
O	488	495	effects	effect	NNS	I-NP
O	496	498	of	of	IN	B-PP
O	499	505	WIT003	WIT003	NN	B-NP
O	506	507	[	[	(	O
O	507	509	20	20	CD	B-NP
O	509	510	-	-	HYPH	I-NP
O	510	523	hydroxyeicosa	hydroxyeicosa	NN	I-NP
O	523	524	-	-	HYPH	B-NP
O	524	525	5	5	CD	I-NP
O	525	526	(	(	(	O
O	526	527	Z	Z	NN	B-NP
O	527	528	)	)	)	O
O	528	529	,	,	,	O
O	529	531	14	14	CD	B-NP
O	531	532	(	(	(	O
O	532	533	Z	Z	NN	B-NP
O	533	534	)	)	)	O
O	534	535	-	-	HYPH	B-NP
O	535	542	dienoic	dienoic	JJ	I-NP
O	543	547	acid	acid	NN	I-NP
O	547	548	]	]	)	O
O	548	549	,	,	,	O
O	550	551	a	a	DT	B-NP
O	552	554	20	20	CD	I-NP
O	554	555	-	-	HYPH	I-NP
O	555	559	HETE	HETE	NN	I-NP
O	560	566	analog	analog	NN	I-NP
O	567	569	on	on	IN	B-PP
O	570	575	human	human	JJ	B-NP
B-Cell	576	589	macrovascular	macrovascular	JJ	I-NP
O	590	592	or	or	CC	I-NP
B-Cell	593	606	microvascular	microvascular	JJ	I-NP
I-Cell	607	609	EC	EC	NN	I-NP
O	609	610	.	.	.	O

O	611	617	WIT003	WIT003	NN	B-NP
O	617	618	,	,	,	O
O	619	621	as	as	RB	B-CONJP
O	622	626	well	well	RB	I-CONJP
O	627	629	as	as	IN	I-CONJP
O	630	634	pure	pure	JJ	B-NP
O	635	637	20	20	CD	I-NP
O	637	638	-	-	HYPH	I-NP
O	638	642	HETE	HETE	NN	I-NP
O	642	643	,	,	,	O
O	644	654	stimulated	stimulate	VBN	B-VP
B-Cell	655	657	EC	EC	NNP	B-NP
O	658	671	proliferation	proliferation	NN	I-NP
O	672	674	by	by	IN	B-PP
O	675	688	approximately	approximately	RB	B-NP
O	689	691	40	40	CD	I-NP
O	691	692	%	%	NN	I-NP
O	692	693	.	.	.	O

O	694	699	These	These	DT	B-NP
O	700	713	proliferative	proliferative	JJ	I-NP
O	714	721	effects	effect	NNS	I-NP
O	722	726	were	be	VBD	B-VP
O	727	738	accompanied	accompany	VBN	I-VP
O	739	741	by	by	IN	B-PP
O	742	751	increased	increase	VBN	B-NP
O	752	756	VEGF	VEGF	NN	I-NP
O	757	767	expression	expression	NN	I-NP
O	768	771	and	and	CC	O
O	772	779	release	release	NN	B-NP
O	780	784	that	that	WDT	B-NP
O	785	789	were	be	VBD	B-VP
O	790	798	observed	observe	VBN	I-VP
O	799	801	as	as	RB	B-ADVP
O	802	807	early	early	RB	I-ADVP
O	808	810	as	as	IN	B-PP
O	811	812	4	4	CD	B-NP
O	813	814	h	h	NN	I-NP
O	815	820	after	after	IN	B-PP
O	821	823	20	20	CD	B-NP
O	823	824	-	-	HYPH	I-NP
O	824	828	HETE	HETE	NN	I-NP
O	829	836	agonist	agonist	NN	I-NP
O	837	845	addition	addition	NN	I-NP
O	845	846	.	.	.	O

O	847	851	This	This	DT	B-NP
O	852	855	was	be	VBD	B-VP
O	856	867	accompanied	accompany	VBN	I-VP
O	868	870	by	by	IN	B-PP
O	871	880	increased	increase	VBN	B-NP
O	881	896	phosphorylation	phosphorylation	NN	I-NP
O	897	899	of	of	IN	B-PP
O	900	903	the	the	DT	B-NP
O	904	908	VEGF	VEGF	NN	I-NP
O	909	917	receptor	receptor	NN	I-NP
O	918	919	2	2	CD	I-NP
O	919	920	.	.	.	O

O	921	924	The	The	DT	B-NP
O	925	938	proliferative	proliferative	JJ	I-NP
O	939	946	effects	effect	NNS	I-NP
O	947	949	of	of	IN	B-PP
O	950	952	20	20	CD	B-NP
O	952	953	-	-	HYPH	I-NP
O	953	957	HETE	HETE	NN	I-NP
O	958	962	were	be	VBD	B-VP
O	963	971	markedly	markedly	RB	I-VP
O	972	981	inhibited	inhibit	VBN	I-VP
O	982	984	by	by	IN	B-PP
O	985	986	a	a	DT	B-NP
O	987	991	VEGF	VEGF	NN	I-NP
O	991	992	-	-	HYPH	O
O	992	1004	neutralizing	neutralize	VBG	B-VP
O	1005	1013	antibody	antibody	NN	B-NP
O	1013	1014	.	.	.	O

O	1015	1027	Polyethylene	Polyethylene	NN	B-NP
O	1028	1034	glycol	glycol	NN	I-NP
O	1034	1035	-	-	HYPH	O
O	1035	1045	superoxide	superoxide	NN	B-NP
O	1046	1055	dismutase	dismutase	NN	I-NP
O	1056	1057	(	(	(	O
O	1057	1060	PEG	PEG	NN	B-NP
O	1060	1061	-	-	HYPH	B-NP
O	1061	1064	SOD	SOD	NN	I-NP
O	1064	1065	)	)	)	O
O	1066	1074	markedly	markedly	RB	B-ADVP
O	1075	1084	inhibited	inhibit	VBD	B-VP
O	1085	1089	both	both	CC	O
O	1090	1093	the	the	DT	B-NP
O	1094	1103	increases	increase	NNS	I-NP
O	1104	1106	in	in	IN	B-PP
O	1107	1111	VEGF	VEGF	NN	B-NP
O	1112	1122	expression	expression	NN	I-NP
O	1123	1126	and	and	CC	O
O	1127	1130	the	the	DT	B-NP
O	1131	1144	proliferative	proliferative	JJ	I-NP
O	1145	1152	effects	effect	NNS	I-NP
O	1153	1155	of	of	IN	B-PP
O	1156	1158	20	20	CD	B-NP
O	1158	1159	-	-	HYPH	I-NP
O	1159	1163	HETE	HETE	NN	I-NP
O	1163	1164	.	.	.	O

O	1165	1167	In	In	IN	B-PP
O	1168	1176	contrast	contrast	NN	B-NP
O	1176	1177	,	,	,	O
O	1178	1192	administration	administration	NN	B-NP
O	1193	1195	of	of	IN	B-PP
O	1196	1199	the	the	DT	B-NP
O	1200	1203	NAD	NAD	NN	I-NP
O	1203	1204	(	(	(	O
O	1204	1205	P	P	NN	B-NP
O	1205	1206	)	)	)	O
O	1206	1207	H	H	NN	B-NP
O	1208	1215	oxidase	oxidase	NN	I-NP
O	1216	1225	inhibitor	inhibitor	NN	I-NP
O	1226	1234	apocynin	apocynin	NN	I-NP
O	1235	1238	had	have	VBD	B-VP
O	1239	1241	no	no	DT	B-NP
O	1242	1248	effect	effect	NN	I-NP
O	1249	1251	to	to	TO	B-PP
O	1252	1255	the	the	DT	B-NP
O	1256	1269	proliferative	proliferative	JJ	I-NP
O	1270	1278	response	response	NN	I-NP
O	1279	1281	to	to	TO	B-PP
O	1282	1284	20	20	CD	B-NP
O	1284	1285	-	-	HYPH	I-NP
O	1285	1289	HETE	HETE	NN	I-NP
O	1289	1290	.	.	.	O

O	1291	1294	The	The	DT	B-NP
O	1295	1297	20	20	CD	I-NP
O	1297	1298	-	-	HYPH	I-NP
O	1298	1302	HETE	HETE	NN	I-NP
O	1303	1310	agonist	agonist	NN	I-NP
O	1311	1319	markedly	markedly	RB	B-ADVP
O	1320	1329	increased	increase	VBD	B-VP
O	1330	1340	superoxide	superoxide	NN	B-NP
O	1341	1350	formation	formation	NN	I-NP
O	1351	1353	as	as	IN	B-SBAR
O	1354	1363	reflected	reflect	VBN	B-VP
O	1364	1366	by	by	IN	B-PP
O	1367	1369	an	an	DT	B-NP
O	1370	1378	increase	increase	NN	I-NP
O	1379	1381	in	in	IN	B-PP
O	1382	1397	dihydroethidium	dihydroethidium	NN	B-NP
O	1398	1406	staining	staining	NN	I-NP
O	1407	1409	of	of	IN	B-PP
B-Cell	1410	1412	EC	EC	NN	B-NP
O	1412	1413	,	,	,	O
O	1414	1417	and	and	CC	O
O	1418	1422	this	this	DT	B-NP
O	1423	1431	increase	increase	NN	I-NP
O	1432	1435	was	be	VBD	B-VP
O	1436	1445	inhibited	inhibit	VBN	I-VP
O	1446	1448	by	by	IN	B-PP
O	1449	1452	PEG	PEG	NN	B-NP
O	1452	1453	-	-	HYPH	O
O	1453	1456	SOD	SOD	NN	B-NP
O	1457	1460	but	but	CC	B-PP
O	1461	1464	not	not	RB	B-PP
O	1465	1467	by	by	IN	I-PP
O	1468	1476	apocynin	apocynin	NN	B-NP
O	1476	1477	.	.	.	O

O	1478	1480	20	20	CD	B-NP
O	1480	1481	-	-	HYPH	I-NP
O	1481	1485	HETE	HETE	NN	I-NP
O	1486	1490	also	also	RB	B-ADVP
O	1491	1500	increased	increase	VBD	B-VP
O	1501	1504	the	the	DT	B-NP
O	1505	1520	phosphorylation	phosphorylation	NN	I-NP
O	1521	1523	of	of	IN	B-PP
O	1524	1527	p42	p42	NN	B-NP
O	1527	1528	/	/	SYM	O
O	1528	1531	p44	p44	NN	B-NP
O	1532	1539	mitogen	mitogen	NN	I-NP
O	1539	1540	-	-	HYPH	B-VP
O	1540	1549	activated	activate	VBN	B-NP
O	1550	1557	protein	protein	NN	I-NP
O	1558	1564	kinase	kinase	NN	I-NP
O	1565	1566	(	(	(	O
O	1566	1570	MAPK	MAPK	NN	B-NP
O	1570	1571	)	)	)	O
O	1572	1574	in	in	IN	B-PP
B-Cell	1575	1577	EC	EC	NN	B-NP
O	1577	1578	,	,	,	O
O	1579	1586	whereas	whereas	IN	O
O	1587	1589	an	an	DT	B-NP
O	1590	1599	inhibitor	inhibitor	NN	I-NP
O	1600	1602	of	of	IN	B-PP
O	1603	1607	MAPK	MAPK	NN	B-NP
O	1608	1609	[	[	(	O
O	1609	1614	U0126	U0126	NN	B-NP
O	1614	1615	,	,	,	O
O	1616	1617	1	1	CD	B-NP
O	1617	1618	,	,	,	I-NP
O	1618	1619	4	4	CD	I-NP
O	1619	1620	-	-	HYPH	I-NP
O	1620	1627	diamino	diamino	NN	I-NP
O	1627	1628	-	-	HYPH	I-NP
O	1628	1629	2	2	CD	I-NP
O	1629	1630	,	,	,	I-NP
O	1630	1631	3	3	CD	I-NP
O	1631	1632	-	-	HYPH	B-NP
O	1632	1639	dicyano	dicyano	AFX	I-NP
O	1639	1640	-	-	HYPH	I-NP
O	1640	1641	1	1	CD	I-NP
O	1641	1642	,	,	,	I-NP
O	1642	1643	4	4	CD	I-NP
O	1643	1644	-	-	HYPH	I-NP
O	1644	1647	bis	bis	NN	I-NP
O	1647	1648	(	(	(	O
O	1648	1649	2	2	CD	B-NP
O	1649	1650	-	-	HYPH	I-NP
O	1650	1665	aminophenylthio	aminophenylthio	NN	I-NP
O	1665	1666	)	)	)	O
O	1666	1675	butadiene	butadiene	NN	B-NP
O	1675	1676	]	]	)	O
O	1677	1687	suppressed	suppress	VBD	B-VP
O	1688	1691	the	the	DT	B-NP
O	1692	1705	proliferative	proliferative	JJ	I-NP
O	1706	1709	and	and	CC	O
O	1710	1713	the	the	DT	B-NP
O	1714	1718	VEGF	VEGF	NN	I-NP
O	1719	1726	changes	change	NNS	I-NP
O	1727	1730	but	but	CC	B-NP
O	1731	1734	not	not	RB	I-NP
O	1735	1738	the	the	DT	B-NP
O	1739	1742	pro	pro	AFX	I-NP
O	1742	1743	-	-	HYPH	I-NP
O	1743	1750	oxidant	oxidant	JJ	I-NP
O	1751	1758	effects	effect	NNS	I-NP
O	1759	1761	of	of	IN	B-PP
O	1762	1764	20	20	CD	B-NP
O	1764	1765	-	-	HYPH	I-NP
O	1765	1769	HETE	HETE	NN	I-NP
O	1769	1770	.	.	.	O

O	1771	1776	These	These	DT	B-NP
O	1777	1781	data	datum	NNS	I-NP
O	1782	1789	suggest	suggest	VBP	B-VP
O	1790	1794	that	that	IN	B-SBAR
O	1795	1797	20	20	CD	B-NP
O	1797	1798	-	-	HYPH	I-NP
O	1798	1802	HETE	HETE	NN	I-NP
O	1803	1813	stimulates	stimulate	VBZ	B-VP
O	1814	1824	superoxide	superoxide	NN	B-NP
O	1825	1834	formation	formation	NN	I-NP
O	1835	1837	by	by	IN	B-PP
O	1838	1846	pathways	pathway	NNS	B-NP
O	1847	1852	other	other	JJ	B-ADJP
O	1853	1857	than	than	IN	B-PP
O	1858	1866	apocynin	apocynin	NN	B-NP
O	1866	1867	-	-	HYPH	B-NP
O	1867	1876	sensitive	sensitive	JJ	I-NP
O	1877	1880	NAD	NAD	NN	I-NP
O	1880	1881	(	(	(	O
O	1881	1882	P	P	NN	B-NP
O	1882	1883	)	)	)	O
O	1883	1884	H	H	NN	B-NP
O	1885	1892	oxidase	oxidase	NN	I-NP
O	1892	1893	,	,	,	O
O	1894	1901	thereby	thereby	RB	B-VP
O	1902	1912	activating	activate	VBG	I-VP
O	1913	1917	MAPK	MAPK	NN	B-NP
O	1918	1921	and	and	CC	O
O	1922	1926	then	then	RB	O
O	1927	1936	enhancing	enhance	VBG	B-VP
O	1937	1941	VEGF	VEGF	NN	B-NP
O	1942	1951	synthesis	synthesis	NN	I-NP
O	1952	1956	that	that	WDT	B-NP
O	1957	1963	drives	drive	VBZ	B-VP
B-Cell	1964	1966	EC	EC	NN	B-NP
O	1967	1980	proliferation	proliferation	NN	I-NP
O	1980	1981	.	.	.	O

O	1982	1986	Thus	Thus	RB	B-ADVP
O	1986	1987	,	,	,	O
O	1988	1990	20	20	CD	B-NP
O	1990	1991	-	-	HYPH	I-NP
O	1991	1995	HETE	HETE	NN	I-NP
O	1996	1999	may	may	MD	B-VP
O	2000	2002	be	be	VB	I-VP
O	2003	2011	involved	involve	VBN	I-VP
O	2012	2014	in	in	IN	B-PP
O	2015	2018	the	the	DT	B-NP
O	2019	2029	regulation	regulation	NN	I-NP
O	2030	2032	of	of	IN	B-PP
B-Cell	2033	2035	EC	EC	NNP	B-NP
O	2036	2045	functions	function	NNS	I-NP
O	2045	2046	,	,	,	O
O	2047	2051	such	such	JJ	B-PP
O	2052	2054	as	as	IN	I-PP
O	2055	2067	angiogenesis	angiogenesis	NN	B-NP
O	2067	2068	.	.	.	O

